SPRYD7

Across TCGA pan-cancer cohorts, SPRYD7 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPRYD7 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SPRYD7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SPRYD7 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where SPRYD7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.647	1.000	.005	33	view →
UCEC	DFS	Median	All	0.969	0.837	.004	22	view →
PDAC	OS	Median	IV	0.381	0.951	.006	15	view →
HNSC	OS	Median	All	1.000	0.959	.023	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPRYD7–CCRCC (OS)

Open the CCRCC breakdown →